Molecular structure and pharmacological activation of LZTR1 towards novel anticancer therapies KU Leuven
GTPases of the RAS family are among the most frequently mutated oncogenes. Their excessive activity results in overstimulation of the MAPK pathway leading to various cancers. While direct targeting of RAS proteins is challenging, this proposal focuses on LZTR1 which was validated as a negative regulator of RAS. LZTR1 promotes the action of CUL3 ubiquitin ligase on substrates including RAS, leading to their degradation. It was shown that the ...